Latest / The Well-Built Life / Breast Cancer Screening: Navigating Risk and Technology
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell alongside Thomas Bennett and we are so glad
- 0:06Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules and
- 0:12Speaker 1: share simple practical habits that help you feel stronger, healthier
- 0:15Speaker 1: and more balanced every single day. Grab a drink, get
- 0:19Speaker 1: comfortable and let's dive in. Let's start by setting the stage.
- 0:23Speaker 1: Recent discussions about breast cancer screening have hit a critical
- 0:27Speaker 1: point thanks to advancements in tech, and increased awareness.
- 0:31Speaker 2: Dr.
- 0:31Speaker 1: Mark Hyman has been leading this conversation with his show,
- 0:35Speaker 1: delving deep into issues like underdiagnosis and access to care. Thomas,
- 0:40Speaker 1: what do you make of the current state of breast
- 0:43Speaker 1: cancer screening?
- 0:44Speaker 2: Exactly. Because on the surface, it looks straightforward. Screen regularly,
- 0:49Speaker 2: catch it early, save lives. But when you dig into
- 0:52Speaker 2: the mechanics, the incentives tell a very different story. For instance,
- 0:57Speaker 2: did you know that 1 in 8 women will develop
- 0:59Speaker 2: breast cancer? That's a stark reality, and it hits home
- 1:02Speaker 2: for everyone, no matter their family history. Right.
- 1:06Speaker 1: And that's the crucial nuance here. Many women think the
- 1:10Speaker 1: absence of a family history eliminates their risk. But according
- 1:14Speaker 1: to Dr. Hyman, 85% of breast cancer cases have no
- 1:18Speaker 1: family history. This is a significant shift in our understanding
- 1:23Speaker 1: and should prompt us to rethink who needs screening. And
- 1:26Speaker 1: how often?
- 1:27Speaker 2: That's wild when you look at the raw numbers. Another
- 1:30Speaker 2: interesting point is that 50% of counties in the U.S.
- 1:33Speaker 2: lack an obstetrician, gynecologist. This means many women, especially in
- 1:39Speaker 2: rural areas, face significant barriers to care. It's not just
- 1:43Speaker 2: about having technology or protocols. It's about ensuring everyone has access.
- 1:48Speaker 1: Exactly. The challenge of access plays a huge role. Standard protocols,
- 1:54Speaker 1: like mammography, every two years are often the go-to. But
- 1:59Speaker 1: they are not perfect. Dr. Hyman points out that mammograms
- 2:03Speaker 1: fail to detect 15 to 25% of cancers, especially in
- 2:08Speaker 1: women with dense breast tissue. This is a real gap.
- 2:12Speaker 1: And it's particularly problematic in younger women, who often have
- 2:16Speaker 1: denser breast tissue.
- 2:17Speaker 2: Right. And that's where technologies like ultrasound and MRI come in.
- 2:23Speaker 2: These can complement mammograms. For example, breast ultrasound can detect
- 2:28Speaker 2: some tumors not visible on mammograms, which is crucial. MRI
- 2:32Speaker 2: is even more sensitive, but is not typically used as
- 2:36Speaker 2: a first-line screening tool due to higher costs and invasiveness.
- 2:40Speaker 1: That's a good segue into the role of AI in imaging.
- 2:44Speaker 1: Advances in 3D mammography are improving detection rates, but adoption
- 2:48Speaker 1: remains slow. AI tech is being integrated to enhance accuracy
- 2:53Speaker 1: and speed. But it's not just about the technology. It's
- 2:57Speaker 1: about making sure these tools are part of our standard care.
- 3:00Speaker 2: Agreed. And let's not forget the lifetime risk assessment models
- 3:04Speaker 2: like the Tire Cusick model. These tools help identify high-risk
- 3:08Speaker 2: individuals who might benefit from earlier or more frequent imaging.
- 3:12Speaker 2: It's all about tailoring screening to individual needs, not applying
- 3:16Speaker 2: one-size-fits-all practices. Exactly.
- 3:19Speaker 1: And this ties back to the core issue of overdiagnosis
- 3:22Speaker 1: and underdiagnosis, standard of care versus reality. It's a tricky balance.
- 3:28Speaker 1: Overdiagnosis can lead to unnecessary treatments, while underdiagnosis can mean
- 3:33Speaker 1: misdiagnosis and worse outcomes.
- 3:36Speaker 2: True, and it's compounded by the cost and convenience of
- 3:39Speaker 2: regular screening. Frequent tests and biopsies can be stressful, and
- 3:43Speaker 2: the emotional toll isn't always considered in screening protocols. It's
- 3:48Speaker 2: an ongoing debate about how we balance prevention with practicality
- 3:51Speaker 2: and patient well-being.
- 3:53Speaker 1: Absolutely. And access to care is a critical piece of
- 3:56Speaker 1: this puzzle. Ensuring everyone has the same opportunities for early
- 4:00Speaker 1: detection and treatment is key. Public health organizations, patient advocates,
- 4:06Speaker 1: and medical technology companies all play vital roles. But we
- 4:11Speaker 1: need systemic changes to make it happen.
- 4:13Speaker 2: Definitely. This brings us to patient agency and decision-making. Empowering
- 4:19Speaker 2: individuals to understand their risk factors and make informed decisions
- 4:23Speaker 2: is crucial. It's not just about following protocol. It's about
- 4:27Speaker 2: taking ownership of your health.
- 4:29Speaker 1: And technology implementation. Integrating new diagnostic tools into current healthcare
- 4:34Speaker 1: systems is challenging. We need robust support for both the
- 4:38Speaker 1: development and the integration of these technologies to ensure they
- 4:43Speaker 1: benefit everyone.
- 4:44Speaker 2: Yes. And moving forward, we see a potential shift towards
- 4:47Speaker 2: more personalized and proactive screening methods. This approach could tailor
- 4:52Speaker 2: interventions based on individual needs. AI and advanced imaging technologies
- 4:57Speaker 2: offer promising solutions, but we need broader adoption and more research.
- 5:02Speaker 1: And as for the future, increased public awareness and education
- 5:07Speaker 1: are essential. We need to educate not just about the
- 5:10Speaker 1: importance of early risk assessment, but also about the lifestyle
- 5:14Speaker 1: factors that can influence risk.
- 5:16Speaker 2: Absolutely. A stronger focus on metabolic health, for instance, could
- 5:21Speaker 2: significantly reduce overall risk. It's a multifaceted approach, but one
- 5:27Speaker 2: that can make a real difference in women's health outcomes.
- 5:30Speaker 1: So let's dig into breast cancer screening mechanisms. Mammography is
- 5:35Speaker 1: the gold standard, right? But its limitations become starkly apparent
- 5:39Speaker 1: in women with dense breast tissue. Can you explain how
- 5:43Speaker 1: the failure rate manifests in this group?
- 5:45Speaker 2: Right.
- 5:46Speaker 1: And that's the crucial nuance here. But how do breast
- 5:50Speaker 1: ultrasounds and MRIs fit into this picture? They are said
- 5:54Speaker 1: to be more effective in women with dense breast tissue,
- 5:57Speaker 1: aren't they?
- 5:58Speaker 2: Exactly. You bring up a great point, Rachel. Ultrasounds are
- 6:01Speaker 2: particularly useful because they can detect tumors that might not
- 6:05Speaker 2: show up on mammograms. MRI, on the other hand, offers
- 6:09Speaker 2: high sensitivity but is more expensive and can be invasive.
- 6:13Speaker 2: It's often used as an add-on to mammography for high-risk
- 6:16Speaker 2: patients or cases where initial findings are ambiguous.
- 6:20Speaker 1: So, speaking of high risk, let's talk about the roles
- 6:23Speaker 1: of 3D mammography and AI. How do these technologies aim
- 6:28Speaker 1: to address the limitations we have discussed?
- 6:30Speaker 2: 3D mammography has indeed improved detection rates by providing a
- 6:34Speaker 2: three-dimensional view making it easier to identify abnormalities. The integration
- 6:40Speaker 2: of AI into these imaging tools further enhances accuracy by
- 6:44Speaker 2: automating the analysis, essentially speeding up the process and potentially
- 6:48Speaker 2: reducing false positives. However, implementation remains a challenge due to
- 6:53Speaker 2: costs and infrastructure.
- 6:55Speaker 1: That's interesting. Let's switch gears a bit. How do personalized
- 7:00Speaker 1: risk assessments like the Tire QSAC model fit into this?
- 7:04Speaker 1: Are they just tools for high-risk individuals, or should everyone
- 7:08Speaker 1: participate in them?
- 7:09Speaker 2: The Tire QSAC model is designed for higher-risk categories, but
- 7:14Speaker 2: it's an excellent starting point for more detailed monitoring. It
- 7:17Speaker 2: focuses on factors like family history, personal characteristics, and other
- 7:22Speaker 2: risk factors. The challenge is in educating patients on how
- 7:26Speaker 2: to interpret these results and make informed decisions. It's also
- 7:30Speaker 2: about ensuring that these assessments are part of a broader,
- 7:34Speaker 2: personalized care strategy.
- 7:36Speaker 1: Absolutely. And on a broader level, how does all this
- 7:40Speaker 1: tie into the larger narrative about breast cancer screening, particularly
- 7:44Speaker 1: in terms of over-diagnosis and under-diagnosis?
- 7:48Speaker 2: Over-diagnosis is a significant concern because of the high number
- 7:52Speaker 2: of false positives leading to unnecessary anxiety and treatments. Underdiagnosis,
- 7:59Speaker 2: especially in younger women due to dense breast tissue, is
- 8:02Speaker 2: equally troubling. We need to find that sweet spot between
- 8:06Speaker 2: unnecessary intervention and delayed diagnosis. That's where personalized risk assessments
- 8:13Speaker 2: and advanced imaging technologies come into play.
- 8:16Speaker 1: True, and we mustn't forget the discussion around patient agency.
- 8:20Speaker 1: How do we empower women to make informed decisions, when
- 8:23Speaker 1: we have such complex screening protocols.
- 8:26Speaker 2: By ensuring that all women are well-informed about their risk factors,
- 8:30Speaker 2: the benefits and limitations of each screening method, and what
- 8:33Speaker 2: the latest technologies can offer, patient education is key. It's
- 8:37Speaker 2: about creating a more proactive and informed approach to healthcare,
- 8:41Speaker 2: making sure every woman feels empowered to make choices that
- 8:44Speaker 2: align with her personal risk profile.
- 8:47Speaker 1: That brings us to the heart of the matter, how
- 8:49Speaker 1: we navigate these latent contradictions in our approach to breast
- 8:52Speaker 1: cancer screening. On one hand, we have the push for
- 8:55Speaker 1: more frequent screening to catch cancers earlier. Yet on the other,
- 9:00Speaker 1: we face the very real risk of overdiagnosis. What do
- 9:03Speaker 1: you think? Thomas, how do we strike the balance?
- 9:07Speaker 2: It's a tricky balance, Rachel. Overdiagnosis can lead to unnecessary
- 9:12Speaker 2: treatments like chemotherapies and surgeries, which can have serious side effects.
- 9:18Speaker 2: But underdiagnosis, as you rightly pointed out, can be just
- 9:22Speaker 2: as perilous. The question is, how do we ensure we
- 9:26Speaker 2: are not overstepping or missing the mark? Let's dive into
- 9:30Speaker 2: the data. Over 50% of women between the ages of
- 9:33Speaker 2: 40 and 70 have dense breast tissue, which significantly impacts
- 9:38Speaker 2: the reliability of mammograms. This density can mimic the appearance
- 9:42Speaker 2: of cancer, leading to a lot of false positives.
- 9:45Speaker 1: Right. And that's where personalized risk assessments become crucial. Tools
- 9:50Speaker 1: like the Tire-Kuzik model can help us navigate these issues.
- 9:54Speaker 1: But isn't it ironic that while these models are available,
- 9:58Speaker 1: they aren't always utilized in routine practice?
- 10:00Speaker 2: Exactly. This brings us to the critical issue of patient agency.
- 10:05Speaker 2: Women need to understand their individual risks and make informed choices.
- 10:10Speaker 2: But here is the catch. Their doctors often aren't equipped
- 10:14Speaker 2: to deliver this kind of nuanced, personalized information. For instance,
- 10:19Speaker 2: just because a woman has a 12.5% lifetime risk of
- 10:22Speaker 2: breast cancer, it doesn't mean she should get the same
- 10:25Speaker 2: screening as someone with a 2.5% risk. True.
- 10:29Speaker 1: And let's not forget the socio-economic factors at play. The Dr.
- 10:34Speaker 1: Hyman show has highlighted the disparity in access to care,
- 10:37Speaker 1: particularly in under-resourced areas. How does this play out in practice?
- 10:43Speaker 1: We have 50% of counties without an OBSIEN. This means,
- 10:48Speaker 1: for many women, regular screenings are out of reach, leading
- 10:52Speaker 1: to underdiagnosis.
- 10:53Speaker 2: Exactly. This underscores the need for a multi-faceted approach. Integrating
- 10:58Speaker 2: technologies like AI and 3D mammography can improve detection rates,
- 11:02Speaker 2: but we need broader implementation and more equitable access. AI
- 11:06Speaker 2: can help by flagging suspicious areas and mammograms, but if
- 11:10Speaker 2: those areas are not followed up due to a lack
- 11:13Speaker 2: of resources, we are still falling short.
- 11:15Speaker 1: And hair is the rub, these technologies, while promising, are
- 11:19Speaker 1: still in the early stages of integration. Take, for example,
- 11:23Speaker 1: the double mastectomy story from Dr.
- 11:25Speaker 2: Hyman.
- 11:26Speaker 1: His decision was driven by a high lifetime risk, despite
- 11:29Speaker 1: no family history, which highlights the need for more personalized
- 11:33Speaker 1: and proactive approaches. We can't just rely on standard protocols
- 11:38Speaker 1: without considering each patient's unique risk profile.
- 11:42Speaker 2: Absolutely. The goal should be to empower women to take
- 11:46Speaker 2: more control. For instance, the Dr. Hyman show suggests that
- 11:50Speaker 2: more women need to calculate their lifetime risk and make
- 11:53Speaker 2: proactive decisions. This approach is more about prevention and early
- 11:58Speaker 2: intervention rather than simply reacting to annual screenings.
- 12:01Speaker 1: Speaking of which, let's not forget about the emotional and
- 12:05Speaker 1: financial toll of over-screening, the stress of frequent tests, the
- 12:09Speaker 1: potential for false positives and unnecessary treatments. these can take
- 12:13Speaker 1: a significant toll on women's lives. The key is finding
- 12:17Speaker 1: a balance that respects individual risk and doesn't overburden the
- 12:20Speaker 1: healthcare system.
- 12:21Speaker 2: Well said. The journey to a more personalized and effective
- 12:25Speaker 2: screening system is long and complex, but it's a journey
- 12:29Speaker 2: worth taking. By focusing on patient education, advanced technology, and
- 12:35Speaker 2: equitable access, we can move closer to a place where
- 12:38Speaker 2: every woman's unique risk profile is taken into account.
- 12:41Speaker 1: Let's dive into some of the key quotes and unsolved
- 12:44Speaker 1: questions that have emerged in the breast cancer screening debate. First,
- 12:49Speaker 1: take a look at this quote from Dr. Hyman. If
- 12:52Speaker 1: I told you you are about to board the plane
- 12:54Speaker 1: with your family members that has a 12.5% chance of crashing,
- 12:59Speaker 1: what would you say? I'd say don't get on that plane.
- 13:02Speaker 2: That analogy is brilliant, Rachel. It speaks to the urgency
- 13:06Speaker 2: of personalized risk assessments, but it also raises a critical question.
- 13:11Speaker 2: When we talk about the 12.5% risk, how do we
- 13:14Speaker 2: ensure every woman is aware of their individual risk factors
- 13:18Speaker 2: beyond just family history? Many women, as Dr. Hyman points out,
- 13:23Speaker 2: might have no apparent risk, yet the overall statistics show
- 13:27Speaker 2: they are still in danger.
- 13:29Speaker 1: Exactly, and this is where the debate gets tricky. How
- 13:32Speaker 1: do we balance the risk of not screening frequently enough
- 13:35Speaker 1: against the potential harm of overdiagnosis? It's a complex calculus,
- 13:40Speaker 1: especially considering the high rate of false positives in mammography,
- 13:43Speaker 1: which can lead to unnecessary treatments and stress.
- 13:46Speaker 2: Absolutely. And the challenge isn't just about the frequency of screenings.
- 13:50Speaker 2: For women with dense breast tissue, the standard mammography can
- 13:54Speaker 2: be significantly less effective. A key issue here is the
- 13:58Speaker 2: balance between the effectiveness of mammography and the necessity of
- 14:01Speaker 2: other imaging techniques like breast ultrasound and MRI. How do
- 14:05Speaker 2: we make the right trade-offs?
- 14:07Speaker 1: Good point, Thomas. To raise a lot of data that
- 14:10Speaker 1: suggests breast ultrasound can be particularly useful in areas where
- 14:14Speaker 1: mammography isn't as reliable. Yet, both tools have their limitations. AI,
- 14:21Speaker 1: especially in three-dimensional mammography, is emerging as a game-changer. but
- 14:26Speaker 1: it's not always integrated into care pathways. How do we
- 14:29Speaker 1: ensure these technologies are accessible and effective?
- 14:34Speaker 2: That's the million-dollar question. Integrating AI into routine care isn't
- 14:39Speaker 2: just about the technology. It's about the infrastructure and the
- 14:42Speaker 2: changes needed in healthcare systems. To raise a critical debate
- 14:46Speaker 2: around the long-term effects of interventions like double mastectomy, Dr.
- 14:50Speaker 2: Hyman's own experience illustrates the complexity. What exactly are the
- 14:54Speaker 2: long-term health outcomes for women who opt for these interventions?
- 14:58Speaker 1: Right, and that's the key. The impact of these decisions
- 15:02Speaker 1: extends far beyond the immediate treatment to raise a real
- 15:05Speaker 1: need for long-term studies to understand the full scope of
- 15:08Speaker 1: these interventions. But we also need to focus on prevention.
- 15:12Speaker 1: How do we empower women to make informed decisions based
- 15:15Speaker 1: on their individual risk factors rather than a blanket approach?
- 15:19Speaker 1: It's a multifaceted challenge.
- 15:23Speaker 2: And it's not just about women, Rachel. The broader issue
- 15:26Speaker 2: of access to care, particularly in regions with fewer OBGYNs,
- 15:30Speaker 2: must be addressed. Ensuring that every woman has access to
- 15:34Speaker 2: the screening and support they need is crucial. It's about
- 15:37Speaker 2: more than just technology. It's about creating a system that
- 15:41Speaker 2: truly serves the needs of all patients.
- 15:43Speaker 1: With the shift towards more personalized methods, it's exciting to
- 15:47Speaker 1: see how AI plays a larger role. Think about how
- 15:51Speaker 1: these advanced algorithms, can analyze not just the images but
- 15:55Speaker 1: also a wide range of biomarkers. Thomas, how does integrating
- 16:00Speaker 1: AI into breast cancer screening change the landscape?
- 16:03Speaker 2: It's a game changer, Rachel. AI can process huge volumes
- 16:07Speaker 2: of data much faster than humans, identifying subtle patterns that
- 16:11Speaker 2: might go unnoticed. For instance, combining AI with mammography can
- 16:15Speaker 2: lead to earlier detection by analyzing not just density but
- 16:19Speaker 2: also microcalcifications that might indicate early cancer stages.
- 16:22Speaker 1: That's wild when you look at the raw numbers. Studies
- 16:26Speaker 1: have shown AI can reduce false negatives by almost 15%.
- 16:30Speaker 1: But it's not just about technology. It's about ensuring equitable
- 16:34Speaker 1: access to this tech, especially in underserved areas.
- 16:37Speaker 2: Exactly equitable access is crucial. It's not just about the
- 16:41Speaker 2: technology being fancy. It's about making sure it reaches those
- 16:45Speaker 2: who need it most. Imagine a system where every patient
- 16:48Speaker 2: gets a tailored risk assessment based on their personal health data, lifestyle,
- 16:53Speaker 2: and family history. Right.
- 16:55Speaker 1: And that's where personalized risk assessment tools come in. Take
- 16:59Speaker 1: the Tire Cusick model you mentioned earlier. It's not just
- 17:03Speaker 1: about blanket yearly screenings. It's about knowing your risk and
- 17:07Speaker 1: adjusting your screening schedule accordingly.
- 17:09Speaker 2: That's the key. For example, a woman with a family
- 17:13Speaker 2: history of cancer might need more frequent screenings, while someone
- 17:17Speaker 2: with a low risk might only need every other year.
- 17:21Speaker 2: This approach could reduce overdiagnosis, which is a real issue
- 17:25Speaker 2: when we rely on one-size-fits-all protocols.
- 17:28Speaker 1: Absolutely. The challenge then is integrating these tools into the
- 17:32Speaker 1: existing healthcare system. We need to ensure that the technology
- 17:36Speaker 1: integrates seamlessly with electronic health records and clinical workflows.
- 17:41Speaker 2: True, and it's not just about the tech. We need
- 17:44Speaker 2: to train healthcare professionals to use these tools effectively. Radiologists,
- 17:48Speaker 2: for instance, need to be adept at interpreting AI-driven results
- 17:52Speaker 2: and combining them with their clinical judgment.
- 17:55Speaker 1: Training is key, Thomas. And then Therese, the matter of
- 17:58Speaker 1: patient education. Women need to understand their individual risks. and
- 18:03Speaker 1: why personalized risk assessments are important.
- 18:06Speaker 2: Exactly, which brings up an interesting contradiction. On one hand,
- 18:11Speaker 2: personalized risk assessments can tailor screening for individual needs, but
- 18:16Speaker 2: on the other, the complexity of this approach might overwhelm
- 18:19Speaker 2: patients and increase anxiety.
- 18:21Speaker 1: That's a valid concern. It's about finding that balance. We
- 18:26Speaker 1: need to empower patients with the information they need, but
- 18:29Speaker 1: also support them in making informed decisions about their health.
- 18:32Speaker 2: Right. And let's not forget the role of public health
- 18:35Speaker 2: organizations in pushing for this system. They can educate the
- 18:39Speaker 2: public and advocate for policies that support the integration of
- 18:42Speaker 2: these technologies.
- 18:43Speaker 1: Agreed. So, we are looking at a future where personalized
- 18:48Speaker 1: risk assessments and advanced technologies become the norm. It's a
- 18:52Speaker 1: shift away from the one-size-fits-all approach and towards a more nuanced,
- 18:58Speaker 1: patient-centered care model.
- 19:00Speaker 2: Absolutely. And it's not just about breast cancer screening. This
- 19:04Speaker 2: shift can influence how we approach other health conditions too.
- 19:08Speaker 2: It's all about moving towards a more proactive data-driven healthcare system.
- 19:12Speaker 1: That brings us to the end of today's episode. Thank
- 19:15Speaker 1: you so much for spending part of your day with me.
- 19:17Speaker 1: If you found this episode's tips helpful and want to
- 19:20Speaker 1: make sure you don't miss the next conversation, please take
- 19:23Speaker 1: a quick second to hit that subscribe or follow button
- 19:26Speaker 1: on whatever platform you are listening on. It's a completely
- 19:29Speaker 1: free way to support the show, and helps more people
- 19:32Speaker 1: find us. This podcast is independently produced, so if you
- 19:36Speaker 1: are ever in a position where you would like to
- 19:38Speaker 1: help keep it running, we do accept small donations. You
- 19:42Speaker 1: can find a link right in the episode description below
- 19:44Speaker 1: to buy us a coffee or contribute what you can.
- 19:48Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 19:53Speaker 1: and we will talk again soon.